GOLGA2P11

Across TCGA pan-cancer cohorts, GOLGA2P11 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated GOLGA2P11 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher GOLGA2P11 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GOLGA2P11 expression acts as an unfavorable survival marker.

LUSC are the cancer types where GOLGA2P11 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.196	0.675	.049	6	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

GOLGA2P11–LUSC (OS)

Open the LUSC breakdown →